Illinois Judge Casts Doubt on Health Plans’ Standing in Biogen Antitrust Suit

An Illinois federal judge expressed doubt over the standing of health benefit plans in an antitrust lawsuit against Biogen. These health benefit plans claim that Biogen hindered competition for its multiple sclerosis drug, Tecfidera. The judge’s skepticism stems from longstanding legal precedents, which traditionally permit only direct purchasers to seek damages in such cases. For more information, the detailed coverage is available on Law360.